the larger middle molecules being diffi cult to remove unless dialyzers with a large pore size are applied (so-called high-fl ux membranes). The protein-bound compounds are diffi cult to remove in spite of low molecular weight because protein binding imposes resistance against transmembrane transfer.
Only a limited fraction of the molecules depicted in the above mentioned encyclopedic review are known end products of oxidative processes. In essence, these are the advanced glycation end products, such as pentosidine and carboxymethyllysine. All other compounds are retained as a result of inadequate clearance by the kidneys and/or defective metabolism as a result of kidney failure. First, peptidic compounds, which are essentially classifi ed as middle molecules, may be present in their genuine form as well as after metabolic transformation; one of the pathways provoking these transformations is caused by oxidation [2, 3] . Second, also other compounds may be modifi ed, at least in part, by oxidation. A third process with potential impact related to oxidation results in the structural alteration of albumin, possibly resulting in the liberation of protein-bound solutes from their binding sites [4] , enhancing their toxic potential. However, in essence, it can be accepted that molecules are at least in part retained in their genuine, unmodifi ed form, and that oxidation cannot explain the entire uremic process.
We will now describe a number of uremic solutes which have been shown to be retained in uremia to exert biological actions that could contribute to the uremic syndrome, and which are very likely not the result of oxidation. Some of these, in being pro-infl ammatory, might induce oxidation themselves.
Exemplary Compounds

Dinucleoside Polyphosphates
Dinucleoside polyphosphates are newly detected protein-bound uremic solutes which are structurally constituted by two nucleosides at both ends of the structure, linked together by a variable number of phosphate moieties [5] . Diadenosine polyphosphates have previously been demonstrated to accumulate in the case of renal failure, especially in the platelets, and to induce smooth muscle cell proliferation [5, 6] .
In this group of compounds, a new molecule was recently detected: uridine adenosine tetraphosphate [7] . It was shown that this compound was present in endothelial cells and released from those cells when they were stimulated. This compound is a much stronger vasoconstrictor than endothelin, a vasoconstrictive peptide which is released by the endothelium as well. The vasoconstrictive effect of uridine adenosine tetraphosphate could be neutralized by specifi c purine receptor antagonists. Uremic concentrations of the latter compound, either intraor extracellular, are not yet known. If we extrapolate the data known for diadenosine polyphosphates, it might however be possible that we are confronted here with a new strong uremic toxin.
Guanidino Compounds
Guanidino compounds are small water-soluble solutes to which neurotoxic effects have been attributed [8] . Many guanidino compounds, especially guanidine, guanidinosuccinic acid and creatinine as a precursor of methylguanidine, as well as methylguanidine itself are highly increased in uremic biological fl uids and tissues [9] .
Until recently, no effects with cardiovascular damaging potential have been attributed to the guanidines, except for asymmetric dimethylarginine [10] , which was shown to inhibit inducible nitric oxide synthase (iNOS) [11] , a protective enzyme of endothelium. However, the concentrations of this compound as they are described in uremia [12] do not necessarily correspond to those inhibiting iNOS [11] .
In a recent study, Glorieux et al. [13] , demonstrated that several other guanidino compounds stimulated leukocytes. Methylguanidine and guanidine stimulated the proliferation of undifferentiated HL-60 cells, and the antiproliferative effect of calcitriol was neutralized in the presence of methylguanidine and guanidinosuccinic acid. The phorbol-myristate-acetate-stimulated chemiluminescence production of differentiated HL-60 cells was enhanced in the presence of guanidine. Methylguanidine and guanidinoacetic acid enhanced the lipopolysaccharide-stimulated intracellular production of tumor necrosis factor-␣ by normal human monocytes. Since atheromatosis is nowadays considered as an infl ammatory disorder whereby adhesion of activated leukocytes to the endothelium induces the fi rst steps towards plaque formation [14] , these compounds have thus a damaging potential on the vessels.
In another recent study, Perna et al. [15] evaluated the impact of a panel of uremic solutes on the structural modifi cation of albumin by deamidation. Plasma proteins from hemodialysis patients showed an increase in deamidated/isomerized asparagine and aspartic acid moieties, and the incubation of normal plasma with various uremic toxins caused a similar deamidation reaction as well. Guanidine and guanidinopropionic acid showed the highest degree of protein modifi cation in a dose-responsive manner. Deamidated human albumin had a reduced binding capacity to homocysteine, hence increasing the toxic potential of this compound.
Guanidino compounds, like urea, are small water-soluble substances and could be expected to show a kinetic behavior similar to that of urea, i.e. an easy removal by any dialysis strategy. Eloot et al. [16] subjected several guanidino compounds such as guanidine, methylguanidine, creatinine, creatine, guanidinosuccinic acid and guanidinoacetic acid to intradialytic kinetic analysis, and compared those kinetics with that of urea. In spite of being water-soluble and small like urea, virtually all guanidino compounds were characterized by a markedly larger distribution volume as compared with urea. The distribution volumes of methylguanidine and guanidinoacetic acid were even more than twice as large as that of urea. This resulted in a dramatic decrease in effective removal which can probably be corrected only by changing the concept of dialysis, essentially by increasing dialysis duration and/or frequency.
In summary, recent data point to a role for guanidino compounds in vascular toxicity, next to their traditionally accepted neurotoxicity. In spite of their physicochemical characteristics which seemingly are comparable with those of urea, their intradialytic behavior is markedly different, so that they can be classifi ed as molecules which are diffi cult to remove. A similar kinetic disparity versus urea has previously been described for other watersoluble compounds, such as phosphate and the purines xanthine and hypoxanthine [17] .
Indoles and Phenols
Indoles and phenols belong to the group of proteinbound solutes which as individual compounds contain a heterogeneous set of molecules, such as p -cresol, indoxyl sulfate, hippuric acid and homocysteine, which are all hard to remove during dialysis [18] .
Multiple toxic effects have been attributed to these compounds, but until recently, no data were available regarding a potential vascular impact, except for homocysteine.
Dou et al. [19] recently investigated the in vitro effect of a large panel of uremic retention solutes on endothelial proliferation and endothelial repair in human umbilical vein endothelial cells. Both these functions were signifi cantly inhibited by indoxyl sulfate. The presence of albumin did not affect the inhibitory effect. Hence, these solutes could play a role in endothelial dysfunction observed in uremic patients.
To these data should be added the studies by D'Hooge et al. [20] , showing neurotoxic effects for indoxyl sulfate, spermine and the phenols, and by Canalejo et al. [21] , showing that HPLC fractions containing protein-bound compounds, and phenol as individual compound, inhibited the regulatory impact of calcitriol on parathyroid gland cells, hence inducing calcitriol resistance.
Of note, two recent clinical studies pointed to a relationship between p -cresol and the clinical condition in uremia [22, 23] .
The potential impact of guanidino compounds on the liberation of homocysteine from its albumin binding sites has already been pointed out above [15] . Further, homocysteine has been linked to altered DNA methylation and altered gene expression patterns, and treatment with folic acid not only decreases plasma homocysteine levels, but also restores DNA and gene expression back to normal [24] .
Recent data indicate that p -cresol, and by extension probably other phenolic compounds as well, do not circulate in the body, but as conjugates, e.g., p -cresol sulfate and p -cresol glucuronide [25] .
Phenylacetic Acid
Phenylacetic acid is a protein-bound compound which is present at increased concentrations in uremic plasma and was shown to inhibit Ca 2+ ATPase [26] . More recently, Jankowski et al. [27] tested the hypothesis that uremic toxins are responsible for reduced iNOS expression. NO prevents atherogenesis and infl ammation in vessel walls by inhibition of cell proliferation and cytokine-induced endothelial expression of adhesion molecules and proinfl ammatory cytokines. Reduced NO production due to inhibition of either endogenous NOS or iNOS may therefore reinforce vascular damage. In the above mentioned study, lipopolysaccharide-induced iNOS expression in mononuclear leukocytes was examined using real-time polymerase chain reaction [27] . The iNOS expression was blocked by addition of plasma from patients with stage 5 renal disease, whereas plasma from healthy controls had no effect. Chromatographic fractionation of hemofi ltrate obtained from patients with stage 5 renal disease revealed a homogenous fraction inhibiting iNOS expression. Using gas chromatography/mass spectrometry, this inhibitor was identifi ed as phenylacetic acid. Authentic phenylacetic acid inhibited iNOS expression dose-dependently. Patients with stage 5 renal failure had a substantial increase in phenylacetic acid serum concentration. Since accumulation of phenylacetic acid in these patients inhibited iNOS expression, this mechanism may contribute to increased atherosclerosis and cardiovascular morbidity in the presence of renal failure.
Unidentifi ed Peptides
Reviewing the uremic retention compounds which have been identifi ed reveals that only close to 100 uremic retention solutes have been described [1] . Very likely, much more compounds are retained in uremia. To examine unknown uremic substances thoroughly, the identification of as many compounds as possible in the ultrafi ltrate and/or plasma of patients would lead to a less biased defi nition of the uremic retention process compared with what is proposed today. Proteomic analysis is a novel tool for the identifi cation of a large number of molecules present in biological fl uids. In a study on ultrafi ltrate from uremic and normal plasma obtained with high-or lowfl ux dialysis membranes, Weissinger et al. [28] used separation by capillary electrophoresis coupled with on-line mass spectrometry, yielding identifi cation of as yet unknown polypeptides based on their molecular weight. Between 500 and 1 1,000 different polypeptides with a molecular weight ranging from 800 to 10,000 Da could be detected in individual samples and were identifi ed via their mass and their particular migration time in capillary electrophoresis. In the ultrafi ltrate from uremic plasma, 1,394 polypeptides were detected in the high-fl ux versus 1,046 in the low-fl ux samples, while 544 versus 490 polypeptides were found in the ultrafi ltrate from normal plasma obtained from membranes with comparable cut-off. In addition, polypeptides 1 5 kDa were virtually only detected in the uremic ultrafi ltrate from the high-fl ux membrane (n = 28 vs. n = 5 with the low-fl ux membrane). To demonstrate the feasibility of further characterizing the detected molecules, polypeptides exclusively present in the uremic ultrafi ltrate were chosen for sequencing analyses. A 950.6-Da polypeptide was identifi ed as a fragment of the salivary proline-rich protein and a 1,291.8-Da fragment was a derivative from ␣ -fi brinogen. These data strongly suggest that the application of proteomic approaches such as capillary electrophoresis and mass spectrometry will result in the identifi cation of many more uremic solutes than those known at present.
It is conceivable that similar strategies might also be useful for the analysis of smaller, non-peptidic compounds. Part of these yet unknown variants might be the result of oxidative modifi cation, as suggested by the presence of several structures which elute close to each other; however, this does not exclude that the genuine mother compounds should be present as well and exert biological activity per se.
Conclusions
Uremic retention corresponds to the accumulation of a host of compounds in the body. Some of these are relatively innocious, such as urea, whereas others exert a myriad of biological and biochemical activities, resulting, at the clinical level, in the uremic syndrome. Unfortunately, our knowledge about the true culprits as well as the spectrum of activities of individual compounds remains largely incomplete. There is an urgent need for a complete mapping and classifi cation of uremic retention compounds according to importance, before the development of therapeutic strategies will exceed the stage of empiricism. To reach this aim, an unbiased approach is needed, avoiding a search for elements whose role is already known to a large extent, if not completely. New research tools such as genomic, functional genomic and proteome analysis are promising strategies to accomplish these aims.
Undoubtedly, part of the retention compounds accumulate because of decreased renal excretion and/or deficient metabolism in the presence of renal failure. On the other hand, these compounds are often present in a proinfl ammatory milieu, which might result in the oxidative modifi cation of retained molecules. Oxidative modifi cations in turn change the properties of retained molecules which might themselves become pro-infl ammatory [29] . It remains diffi cult to perceive whether all noxious substances are the result of oxidation, and even if this would be the case, the harmful effect of such a sequence is largely aggravated by the increased concentrations, merely due to the retention process per se.
It might be interesting to transfer these ideas to the clinical problem which is as of today one of the greatest concerns for the nephrological community: the enhanced cardiovascular risk in uremia. Patients with renal failure are prone to develop cardiovascular problems and these start long before the dialysis stage has been reached. Moreover, the weight of kidney failure in its relation to cardiovascular risk remains, even if corrections are applied for traditional as well as less traditional risk factors. Subsequently, it is acceptable that renal failure per se is also a cause of vascular lesions, and if this is the case, it is conceivable that vascular damage is provoked by the factors retained in renal failure.
Some of these factors, as well as their potential role in cardiovascular damage, are known and might be related to functional changes in white blood cells, platelets, smooth muscle cells and endothelium [30] . While reviewing these factors in 2001 [30] , it became already clear that most factors involved were either larger 'middle' molecules or protein-bound molecules. The data reviewed at present add to this perception. The only solutes which do not conform with this defi nition are the guanidino compounds, but according to kinetic studies, these substances show a kinetic behavior that is divergent from the standard small water-soluble compound, which is urea. Hence, most or at least a substantial part of molecules involved in uremic toxicity and vascular damage seem to be difficult to remove, so that standard dialytic approaches might be less relevant. Therefore, alternative approaches such as convective strategies, treatment with extremely open membranes which are permeable for proteins, adsorption, alternative timeframes (long slow dialysis, daily dialysis) and medicamentous approaches aiming at blockage of receptors and activation pathways induced by toxins as well as at modifi cation of the metabolic generation or breakdown of those toxins are needed.
Part of these molecules are the result of oxidation. A typical example are the advanced glycation end products, which have been shown to increase the baseline activity of white blood cells [29, 31, 32] . The reported data show that such effects cannot be expected from oxidation alone, and at least part of the damage is due to mere retention.
In parallel to these efforts, a more complete mapping of responsible toxins and a classifi cation of their importance should be pursued as well.
